SOURCE: Crucell N.V.

June 02, 2006 02:05 ET

Crucell Supervisory Board Chairman Mr Pieter Strijkert to Step Down; Succeeded by Mr Jan Oosterveld


Leiden, The Netherlands, June 2, 2006 - The Supervisory Board of Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) announced that its chairman, Mr Pieter Strijkert, will step down and be succeeded by fellow Supervisory Board member Mr Jan Oosterveld.

Mr Strijkert has served as chairman of Crucell's Supervisory Board since the Company's incorporation. He also served as chairman of the Supervisory Board of Crucell's predecessor, IntroGene BV, from 1994 to October 2000.

Mr Oosterveld joined the Supervisory Board in 2004. He is also a member of the Boards of Barco (Belgium), Atos Origin (France), Cookson Group (UK), and Continental (Germany).

About Crucell

Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes vaccines against hepatitis B and virosomal influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine on the market. The Company has a broad development pipeline, including both early-stage products and products almost ready to go to market. Several Crucell products are based on its unique PER.C6® production technology. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, GSK and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, elsewhere in Europe, and in Korea. The Company employs about 900 people. For more information, please visit

Forward-looking statements

This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20- F, as filed with the U.S. Securities and Exchange Commission on April 14, 2005, and the section entitled "Risk Factors". The company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP).

For further information please contact:

Crucell N.V.
Harry Suykerbuyk
Director Investor Relations and Corporate Communications
Tel. +31-(0)71-524 8718

For Crucell in the US:
Redington, Inc.
Thomas Redington
Tel. +1 212-926-1733

Copyright © Hugin ASA 2006. All rights reserved.

Contact Information